Satraplatin demonstrates clinical benefit in patients with advanced hormone-refractory prostate cancer: Results of the global phase III satraplatin and prednisone against refractory cancer (sparc) trial

被引：0
|
作者：
Sartor, O.
Petrylak, D.
Witjes, F.
Berry, W.
Chatta, G.
Vaughn, D.
Sternberg, C. N.
机构：
来源：
CANCER INVESTIGATION | 2007年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：19 / 20
页数：2
相关论文
共 50 条
  • [31] A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Lin, Amy M.
    Rini, Brian I.
    Derynck, Mika K.
    Weinberg, Vivian
    Park, Margaret
    Ryan, Charles J.
    Rosenberg, Jonathan E.
    Bubley, Glenn
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2007, 5 (05) : 323 - 328
  • [32] A phase II trial of CI-958 in patients with hormone-refractory prostate cancer
    Woolley, PV
    Freiha, FS
    Smith, DC
    Carlson, L
    Hofacker, J
    Quinn, N
    Grove, W
    Trump, DL
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) : 511 - 517
  • [33] A phase II trial of CI-958 in patients with hormone-refractory prostate cancer
    Paul V. Woolley
    Fuad S. Freiha
    David C. Smith
    Lynn Carlson
    Janie Hofacker
    Nancy Quinn
    William Grove
    Donald L. Trump
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 511 - 517
  • [34] Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: A randomized phase II trial
    Boccardo, Francesco
    Rubagotti, Alessandra
    Conti, Giario
    Battaglia, Michele
    Cruciani, Giorgio
    Manganelli, Antonio
    Ricci, Sergio
    Lapini, Alberto
    ONCOLOGY, 2008, 74 (3-4) : 223 - 228
  • [35] SUNITINIB IN COMBINATION WITH DOCETAXEL AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC)
    Zurita, A. J.
    Logothetis, C. J.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Chen, I.
    Chow-Maneval, E.
    George, D. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 198 - 198
  • [36] Radium-223 might benefit patients with hormone-refractory prostate cancer
    不详
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (10): : 523 - 524
  • [37] Radium-223 might benefit patients with hormone-refractory prostate cancer
    Nature Clinical Practice Urology, 2007, 4 : 523 - 524
  • [38] Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
    L Galli
    A Fontana
    C Galli
    L Landi
    E Fontana
    A Antonuzzo
    M Andreuccetti
    E Aitini
    R Barbieri
    R Di Marsico
    A Falcone
    British Journal of Cancer, 2007, 97 : 1613 - 1617
  • [39] Vinorelbine, mitoxantrone and prednisone (VMP) or mitoxantrone and prednisone (MP) in patients with hormone-refractory prostate cancer (HRPC)
    Pasinetti, Nadia
    Amoroso, Vito
    Ferrari, Vittorio D.
    Simoncini, Edda
    Farisoglio, Camillo
    Valcamonico, Francesca
    Grisanti, Salvatore
    Vassalli, Lucia
    Rangoni, Giovanni
    Marini, Giovanni
    ANNALS OF ONCOLOGY, 2005, 16 : 83 - 83
  • [40] Update in the management of patients with hormone-refractory prostate cancer
    Moore, CN
    George, DJ
    CURRENT OPINION IN UROLOGY, 2005, 15 (03) : 157 - 162
12345